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Comparison of the allele frequencies of the MIF microsatellite
Controls THR
Women Men Women Men
Allele Count Freq Count Freq Count Freq Count Freq
5 1402 25.4 1439 25.3 671 23.1 474 24.3
6 3453 62.5 3574 62.7 1853 63.7 1237 63.5
7 669 12.1 685 12.0 386 13.3 237 12.2
Total 5524 5698 2910 1948
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A197IX (COL9A1), IL1B, and matrix metalloproteinase-13 (MMP13) gene
expression were measured using SYBR Green-based qRT-PCR and were
correlated with methylation status analysed by pyrosequencing
methodology.
Results: Hypoxia resulted in a >50-fold and >10-fold increase in rela-
tive expression of COL9A1 and IL1B respectively. This was inversely
correlated to the DNA methylation status of these genes. Expression of
MMP13 was reduced at 2% oxygen tension in control cells. Relative
expression of MMP13 increased in cells stimulated with IL-1b and 5-
aza-dC in normoxic conditions, and this effect was eliminated at low
oxygen tension although no correlation with methylation status was
observed.
Conclusions: These ﬁndings demonstrate a role for hypoxia in the
regulation anabolic and catabolic gene expression and the inﬂuence of
changes in DNA methylation. These results further support the role of
epigenetics in OA and critically, highlight the complex relationship
between the physiological environment of cartilaginous cells and the
osteoarthritic process with implications for therapeutic intervention
and our understanding of OA pathophysiology.
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VALIDATION OF THE ASSOCIATION OF A FUNCTIONAL
MICROSATELLITE IN MACROPHAGE MIGRATION FACTOR WITH HIP
OA
A. Gonzalez, L. Vidal, M. Calaza. Hosp. Clinico Univ.rio de Santiago,
Santiago de Compostela, Spain
Purpose: Microsatellites are not amenable for high-throughput geno-
typing and have been excluded from GWAS. However, several micro-
satellites have been found to affect expression of nearby genes and a
couple of them, in the asporin and BMP5 genes, have been associated
with susceptibility to OA in multiple studies. In a recent exploration of
functional microsatellites we found association of the -794 CATT
microsatellite in the MIF gene with hip OA in 1782 patients compared
with 1878 healthy controls of European ancestry. Replication in other
patient collections was hampered by the lack of a method to obtain the
genotypes without actually performing the laboratory tests. Therefore,
we aimed to develop an imputation methodology for this microsatellite
using the genotypes of SNPs in linkage disequilibrium and to apply it for
validation.
Methods: In our previous study of the MIF microsatellite, we had
included 1090 samples that were also in the arcOGENGWAS. Genotypes
of the 130 SNPs in the linkage disequilibrium region surrounding the
microsatellite in these samples were used as source of haplotype
information. Imputation was done with Impute2 with modiﬁcations
allowing estimation of the probabilities for the number of copies of each
microsatellite allele and their posterior combination. Performance of
this procedure was evaluated in 10 replicates of training, with 90 % of
the samples, and testing of accuracy in the remaining 10 % of the
samples with known microsatellite genotypes. Once concordance of
imputed genotypes with tested genotypes was established, the
approach was applied for the imputation of the MIF microsatellite in
5667 population controls from Wellcome Trust Case-Control Con-
sortium (WTCCC) and in 2466 hip OA cases from arcOGEN (all of them
of European UK ancestry). In addition, we have validated the functional
effect of the MIF microsatellite on the plasma levels of MIF in 361
healthy control samples by ELISA (R&D Systems) from subjects that
were either homozygous for the 5 repeat or the 6 repeat alleles. MIF
microsatellite allele frequencies were compared with POWERMARKER
and differences in plasma levels of MIF were analyzed with ANOVA
using Statistica 7.0 (StatSoft).
Results: There was a microsatellite allele with frequency lower than 1%
that was not included in the imputation. The genotypes of the other
three alleles were imputedwith sufﬁcient accuracy (91.6 %) and call rate
in the reference samples (98.8). However, other microsatellites showed
that the procedure will require further reﬁnements to attain this per-
formance for microsatellites with more alleles. Application of this
procedure to theWTCCC and arcOGEN samples produced genotypes for
99.0 % of the samples. Comparison of the allelic frequencies showedsigniﬁcant differences between hip OA and controls in women (Table 1)
following the same pattern found in our previous study, with the ﬁve
repeats allele less frequent in the patients than in the controls (OR ¼
0.88, [95% CI] 0.79 to 0.98, P ¼ 0.018). However, no difference was
appreciated in men or between control women andmen as it was in our
previous study. This contrast between studies could be attributed to the
use of OA-free controls in the previous study and population controls
here.
Analysis of MIF in plasma of healthy controls showed higher levels in
the homozygous for the 5 repeat allele (3.6 ng/mL) than for the 6 repeat
allele (2.7 ng/mL; P ¼ 0.00025) following the direction previously
reported by other authors andwithout differences betweenwomen and
men.
Conclusions: A new method to impute genotypes of microsatellites
with three alleles based on SNP genotypes has been developed. It has
shown good call rate and accuracy. This procedure allowed us to vali-
date the association of the MIF microsatellite with hip OA in a large
number of cases and controls. Concordance with our previous study
was obtained in women, but not in men. Higher MIF levels were found
in the subjects with the hip OA protective allele. These results should
contribute to deﬁne the role of MIF, an important cytokine, in the OA
pathology.Health Services Research
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ALTERNATIVE SURVIVAL ANALYSIS METHODS TO ESTIMATE TIME TO
REVISION FOLLOWING HIP AND KNEE ARTHROPLASTY: CAN THE
KAPLAN-MEIER METHOD COMPETE?
S. Lacny y, P.D. Faris z,x, E. Bohm k,¶, L.J. Woodhouse#,yy,
O. Robertsson zz, D.A. Marshall y,xx. yUniv. of Calgary, Calgary, AB,
Canada; zAlberta Hlth.Services, Calgary, AB, Canada; xAlberta Bone and
Joint Hlth.Inst., Calgary, AB, Canada; kUniv. of Manitoba, Winnipeg, MB,
Canada; ¶Concordia Hip and Knee Inst., Winnipeg, MB, Canada; #Univ.
of Alberta, Edmonton, AB, Canada; yyAlberta Hlth.Services Bone and
Joint Hlth.Strategic Clinical Network, Edmonton, AB, Canada; zz Swedish
Knee Arthroplasty Register, Univ. of Lund, Lund, Sweden; xxMcCaig Inst.
for Bone and Joint Hlth., Calgary, AB, Canada
Purpose: With increased longevity and frequency with which joint
replacements are being performed on younger, more physically active
patients, it has become common for patients to outlive the life of their
prosthesis and require a revision. Measuring the cumulative incidence
of revision (i.e., revision rate) provides a measure of the rate of failure
of joint replacements and can be used to project future demand for
revisions. Due to varying patient follow-up times and censoring, sur-
vival analysis is required to estimate revision rates. The Kaplan-Meier
(KM) method is the most commonly applied survival analysis method.
However, it does not account for the competing risk of death and
consequently overestimates the cumulative incidence of revision. This
is problematic given the high rate of competing risks, especially in
older patients receiving joint replacements. Although alternative
methods that account for competing risks have been developed, they
are rarely used within the arthroplasty literature or among joint
replacement registries. Our objective was to assess alternative meth-
ods for estimating the cumulative incidence of revision through
application to population-based cohorts. We evaluated these methods
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A198using hip and knee replacement data from Alberta, Canada, over a 10
year period and knee replacements recorded in the Swedish Knee
Arthroplasty Register (SKAR) over 24 years. We recommend a pre-
ferred method for accurately estimating the cumulative incidence of
revision that can be used to inform health policy decisions and future
resource allocation.
Methods: We measured the time to revision, death, or censoring for
cohorts of uncemented total hip (n¼12,496) and cemented total knee
arthroplasties (TKAs) (n¼19,172) recorded in administrative inpatient
databases in Alberta from 2003 to 2013 and cemented TKAs
(n¼80,177) recorded in the SKAR from 1989 to 2012. Each cohort
included primary unilateral procedures in patients with osteoarthritis.
We estimated the unadjusted cumulative incidence of revision using
the KM failure function (1-KM) and the cumulative incidence function
(CIF), which accounts for competing risks. To quantify the over-
estimation of the KM method compared to the CIF, we calculated the
relative difference (RD) ([{1-KM}-CIF]/CIF) between estimates at ﬁve,
nine, and 23 years (Swedish knee cohort only) following primary
surgery. We also compared three regression models that accounted for
competing risks: the Cox proportional hazards model, Fine and Gray
subdistribution hazards model, and Royston and Parmar ﬂexible
parametric model. We adjusted for age, sex, Charlson Comorbidity
Score (Alberta cohorts only) and year of primary operation (Swedish
cohort only). To examine differences between regression models, we
compared the magnitude of coefﬁcients (hazard ratio [HR] for the Cox
and Royston and Parmar models, subdistribution HR for the Fine and
Gray model), standard errors (SE), and Wald statistic P-values. Our
base case analysis included primary unilateral operations only. In
sensitivity analysis, we included unilateral and staged-bilateral oper-
ations to compare the performance of each model using larger sample
sizes and where the assumption of independence between subjects
was violated.
Results: The KM method and CIF produced similar estimates at fol-
low-up times shorter than 10 years for all three cohorts, although the
KM cumulative incidence was greater than the CIF at each time point.
The magnitude of overestimation at each follow-up time was greatest
for the Swedish cohort, which also had the highest cumulative inci-
dence of death. The extent of overestimation also increased with
follow-up time and became substantial beyond 10 years. At ﬁve years,
the relative increase in estimation of the cumulative incidence esti-
mated using the KM method compared to the CIF for the Alberta hip,
Alberta knee, and Swedish knee cohorts was 1.8%, 2.3%, and 3.8%,
respectively. At nine years, the RDs increased to 3.1%, 5.8%, and 8.2%,
respectively. At 23 years, the RD for the Swedish cohort reached 39.1%,
where the cumulative incidence estimated using the KM method was
7.4% compared to 5.3% for the CIF. Each adjusted regression model
yielded similar coefﬁcients, SEs, and P-values for our base caseTable 1. Six-month Medication and Nutraceutical Costs by Demographic and Clinical
N Medication Cost (US dollar)
Median P25 P75
All 204 962 151 2,781
Gender
Male 61 905 153 4,387
Female 143 991 151 2,491
Race
White 107 911 181 3,061
Black 72 989 212 2,697
Asian 6 177 9 318
Other 19 1,046 0 3,893
WOMAC Pain Score (0-500)
Tertile 1 (least pain) 68 1,018 137 2,491
Tertile 2 68 909 108 2,595
Tertile 3 (most pain) 67 1,013 223 3,646
WOMAC Function Score (0-1700)
Tertile 1 (most function) 68 1,064 164 3,161
Tertile 2 68 962 47 2,871
Tertile 3 (least function) 68 878 234 2,577
Beck II Score (0-63)
13 (no depression) 163 849 135 2,489
 14 (depression) 41 1,312 332 5,214analysis. However, in our sensitivity analysis the Fine and Gray sub-
distribution HR for sex deviated from the HRs obtained from the Cox
and Royston and Parmar models (P¼0.365, P¼0.039, P¼0.045,
respectively).
Conclusions: Our results support the application of the CIF and com-
peting risks regression models to more accurately estimate the cumu-
lative incidence of revision following joint replacement surgery.
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ECONOMIC BURDEN OF MEDICATIONS AND NUTRACEUTICALS IN
KNEE OSTEOARTHRITIS
N. Zhao y, M. Chung y, J.B. Wong z, C. Wang z. yDept. of Publ. Hlth.and
Community Med., Sch. of Med., Tufts Univ., Boston, MA, USA; z Tufts
Med. Ctr./Tufts Univ., Boston, MA, USA
Purpose: For the pain and physical function limitations from knee
osteoarthritis (OA), we have previously reported that both pain and
non-pain medications and nutraceuticals (i.e., dietary supplements)
were more commonly used by patients enrolled in our randomized
clinical trial than that reported in the Osteoarthritis Initiative (Arthritis
Research & Therapy 2013, 15:R106). The aim of this analysis was to
determine the economic cost of those medications and nutraceutical
products and to assess the association of patient demographic and
clinical characteristics with costs.
Methods: Using the Health Assessment Questionairre (HAQ) health
utilization form, persons whomet ACR criteria for knee OA patients and
enrolled in a Tai Chi versus physical therapy for knee osteoarthritis trial
reported their use of prescription and over-the-counter medications
and nutraceutical products during the prior 6 months. Costs were
assigned using the average wholesale price (AWP) from Micromedex
2.0 Red Book Online for medications and ConsumerLab.com® or Ama-
zon for nutraceuticals. Costs accounted for dose and frequency. Because
the distributions of medication and nutraceutical costs were skewed,
we report median and interquartile range (IQR) summary descriptive
results and performed generalized linear model (GLM) regression with
log link function. All p-values were two tailed.
Results: In the 204 knee OA patients included in the present analysis
(mean age 60.2 years, 70% female, mean±SDWOMAC pain 254±95 and
WOMAC function 899±352). 157 (77%), 166 (81%), 150 (74%) reported
taking at least one pain, non-pain medication, or nutraceutical (7%
glucosamine), respectively. Each patient used a median of 4 (IQR: 2-6)
medications and 2 (IQR: 0-4) nutraceutical products. Estimated 6-
month costs for medications and nutraceuticals were $962 (IQR: $152-
$2,781) and $27 (IQR: $0-$86), respectively, yielding a combined total
cost of $989 (IQR: $240-$2,865). The Table summarizes the estimated 6-
month medication and nutraceutical costs by demographic and clinicalCharacteristics
Nutraceutical Cost (US dollar) Total Cost (US dollar)
Median P25 P75 Median P25 P75
27 0 86 989 241 2,865
24 0 75 905 177 4,387
33 2 106 1,004 252 2,745
47 16 122 1,004 261 3,123
22 0 64 989 287 2,719
24 0 38 201 27 1,086
15 0 68 1,113 106 3,953
46 22 111 1,031 257 2,674
24 0 86 909 226 2,643
22 0 62 1,029 261 3,661
37 18 100 1,121 250 3,223
24 0 86 1,027 141 2,993
22 0 75 878 336 2,610
29 0 88 905 228 2,540
24 0 77 1,363 374 5,251
